Strategic implications
For healthcare systems: The convergence of cardiorenal-metabolic disease demands integrated care models across primary and specialty care. With overlap between patients with CKD, HF and other metabolic conditions, treating these as separate conditions in separate clinics increasingly misaligns with clinical reality.
For payer organisations: Coverage frameworks built on single-disease models increasingly misalign with patient complexity. Value assessment must evolve to capture benefits across the cardiorenal-metabolic spectrum, not single indications. This is particularly true in CKD and HF, where organ damage requires multiple mechanisms of action — unlike metabolic conditions where single agents may suffice. The challenge intensifies with combination therapy. While evidence increasingly shows these therapies work best together, each addition layers on cost and complexity.
For pharmaceutical organisations: The opportunity isn’t in dominance among therapeutic classes, but in establishing the right placement of a therapy within a combination-led treatment landscape. Evidence generation must demonstrate not just efficacy, but how therapies enhance outcomes when added to evolving standards of care.
For healthcare systems: The convergence of cardiorenal-metabolic disease demands integrated care models across primary and specialty care. With overlap between patients with CKD, HF and other metabolic conditions, treating these as separate conditions in separate clinics increasingly misaligns with clinical reality.
Q.
How do we optimise cardiorenal-metabolic patient journeys for those who don't fit neat diagnostic categories?
For payer organisations: Coverage frameworks built on single-disease models increasingly misalign with patient complexity. Value assessment must evolve to capture benefits across the cardiorenal-metabolic spectrum, not single indications. This is particularly true in CKD and HF, where organ damage requires multiple mechanisms of action — unlike metabolic conditions where single agents may suffice. The challenge intensifies with combination therapy. While evidence increasingly shows these therapies work best together, each addition layers on cost and complexity.
Q.
How do we develop value frameworks that reward comprehensive cardiorenal-metabolic management while maintaining sustainable access?
For pharmaceutical organisations: The opportunity isn’t in dominance among therapeutic classes, but in establishing the right placement of a therapy within a combination-led treatment landscape. Evidence generation must demonstrate not just efficacy, but how therapies enhance outcomes when added to evolving standards of care.
Q.
Which endpoints - hard outcomes, composite cardio-kidney endpoints, or patient-reported outcomes - will convince payers and guideline committees of additive value in multi-therapy regimens?
How do we optimise cardiorenal-metabolic patient journeys for those who don't fit neat diagnostic categories?
How do we develop value frameworks that reward comprehensive cardiorenal-metabolic management while maintaining sustainable access?
Which endpoints - hard outcomes, composite cardio-kidney endpoints, or patient-reported outcomes - will convince payers and guideline committees of additive value in multi-therapy regimens?
